JP2016536288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536288A5 JP2016536288A5 JP2016521765A JP2016521765A JP2016536288A5 JP 2016536288 A5 JP2016536288 A5 JP 2016536288A5 JP 2016521765 A JP2016521765 A JP 2016521765A JP 2016521765 A JP2016521765 A JP 2016521765A JP 2016536288 A5 JP2016536288 A5 JP 2016536288A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- hydrogen
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 134
- 229910052739 hydrogen Inorganic materials 0.000 claims 96
- 239000001257 hydrogen Substances 0.000 claims 92
- 150000002431 hydrogen Chemical class 0.000 claims 56
- -1 R 5A is H Chemical group 0.000 claims 47
- 125000005843 halogen group Chemical group 0.000 claims 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 36
- 125000003107 substituted aryl group Chemical group 0.000 claims 34
- 125000003342 alkenyl group Chemical group 0.000 claims 32
- 150000001413 amino acids Chemical class 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 19
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 229910052698 phosphorus Inorganic materials 0.000 claims 5
- 239000011574 phosphorus Substances 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 241000710781 Flaviviridae Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890136P | 2013-10-11 | 2013-10-11 | |
| US61/890,136 | 2013-10-11 | ||
| US201462016288P | 2014-06-24 | 2014-06-24 | |
| US62/016,288 | 2014-06-24 | ||
| PCT/US2014/059849 WO2015054465A1 (en) | 2013-10-11 | 2014-10-09 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536288A JP2016536288A (ja) | 2016-11-24 |
| JP2016536288A5 true JP2016536288A5 (enExample) | 2017-12-14 |
| JP6562908B2 JP6562908B2 (ja) | 2019-08-21 |
Family
ID=52810177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521765A Active JP6562908B2 (ja) | 2013-10-11 | 2014-10-09 | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9862743B2 (enExample) |
| EP (1) | EP3055319A4 (enExample) |
| JP (1) | JP6562908B2 (enExample) |
| KR (1) | KR102314960B1 (enExample) |
| CN (2) | CN105829333A (enExample) |
| AU (3) | AU2014331863C1 (enExample) |
| CA (1) | CA2927010C (enExample) |
| CL (1) | CL2016000805A1 (enExample) |
| EA (1) | EA201690526A1 (enExample) |
| IL (1) | IL245014B (enExample) |
| MX (2) | MX382419B (enExample) |
| PE (1) | PE20160658A1 (enExample) |
| PH (1) | PH12016500660A1 (enExample) |
| SG (2) | SG10201804835VA (enExample) |
| TW (1) | TW201524990A (enExample) |
| WO (1) | WO2015054465A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011305652B2 (en) | 2010-09-22 | 2016-10-20 | Janssen Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| SG188497A1 (en) | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
| EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| EP3235824B1 (en) * | 2012-11-16 | 2019-03-27 | University College Cardiff Consultants Limited | Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate |
| ES2865402T3 (es) * | 2012-12-21 | 2021-10-15 | Janssen Biopharma Inc | 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC |
| EP2935305A4 (en) | 2012-12-21 | 2016-08-03 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| EP3013340B9 (en) * | 2013-06-26 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| TWI655199B (zh) | 2013-06-26 | 2019-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| PH12016501567B1 (en) | 2014-02-06 | 2023-12-06 | Riboscience Llc | 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication |
| AU2015280248B2 (en) | 2014-06-24 | 2021-04-08 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CA2952812A1 (en) * | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
| NZ727582A (en) | 2014-06-24 | 2018-06-29 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| PE20170698A1 (es) | 2014-09-26 | 2017-06-05 | Riboscience Llc | Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41213A (fr) * | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| EP3344642A1 (en) | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Anti-viral tetrahydrofurane derivatives |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| KR101785475B1 (ko) | 2015-12-23 | 2017-10-16 | (주)다산메디켐 | 항바이러스성 화합물 |
| US9988416B2 (en) | 2016-03-24 | 2018-06-05 | Novartis Ag | Alkynyl nucleoside analogs as inhibitors of human rhinovirus |
| KR102136803B1 (ko) * | 2016-03-31 | 2020-07-22 | 로마크 레버러토리즈, 엘.씨. | 바이러스 감염을 치료하기 위한 티아졸리드 화합물 |
| US11192914B2 (en) * | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| CN106279321A (zh) * | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
| WO2018031818A2 (en) | 2016-08-12 | 2018-02-15 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| CA3047373A1 (en) * | 2016-12-16 | 2018-06-21 | Gifu University | Nucleoside derivative and use thereof |
| CN108299532B (zh) * | 2016-12-29 | 2020-12-22 | 广东东阳光药业有限公司 | 一种抗病毒核苷类似物前药及其组合物、用途 |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| AU2018312224A1 (en) | 2017-07-31 | 2020-02-27 | January Therapeutics, Inc. | Organophosphate derivatives |
| AU2018332540B2 (en) | 2017-09-18 | 2023-10-05 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP7173467B2 (ja) | 2017-10-31 | 2022-11-16 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| KR20200140274A (ko) * | 2018-03-07 | 2020-12-15 | 에모리 유니버시티 | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| WO2019237297A1 (en) * | 2018-06-14 | 2019-12-19 | Janssen Pharmaceuticals, Inc. | Processes for preparing compounds/intermediates useful in the treatment of viral infections |
| US11834469B2 (en) * | 2018-08-06 | 2023-12-05 | Skylark Bioscience Llc | AMP-activated protein kinase activating compounds and uses thereof |
| WO2020041051A1 (en) * | 2018-08-20 | 2020-02-27 | Cure Biopharma Inc. | Gemcitabine prodrugs |
| AU2020231934B2 (en) | 2019-03-06 | 2023-04-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| CA3153281A1 (en) * | 2019-10-08 | 2021-07-08 | George R. Painter | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2021101469A1 (en) * | 2019-11-21 | 2021-05-27 | Gaziantep Universitesi Rektorlugu | A drug for anticancer and antiviral treatment and synthesis method thereof |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) * | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| KR20250111239A (ko) | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN114796256B (zh) * | 2021-01-29 | 2023-12-08 | 武汉大学 | 环腺苷酸类化合物在制备抗寨卡病毒药物中的应用 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202400134A (zh) | 2022-03-15 | 2024-01-01 | 美商羅米醫療公司 | 用於治療疾病之化合物及方法 |
| CN115322170B (zh) * | 2022-08-29 | 2023-06-02 | 苏州华一新能源科技股份有限公司 | 一种硫酸乙烯酯的制备方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS552601A (en) | 1978-06-20 | 1980-01-10 | Yamasa Shoyu Co Ltd | Anti-tumor agent for non-injection use |
| US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
| US6110901A (en) * | 1990-07-03 | 2000-08-29 | American Cyanamid Company | Method for treating RNA viral infections by using RNA chain terminators |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| JPH07242544A (ja) | 1994-03-01 | 1995-09-19 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
| RU2186569C2 (ru) | 1996-01-23 | 2002-08-10 | Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах |
| CA2266889A1 (en) | 1996-10-16 | 1998-04-23 | Guangyi Wang | Purine l-nucleosides, analogs and uses thereof |
| CA2267279A1 (en) | 1996-10-16 | 1998-04-23 | Devron Averett | Monocyclic l-nucleosides, analogs and uses thereof |
| US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| WO1999061583A2 (en) | 1998-05-28 | 1999-12-02 | Incara Pharmaceuticals Corp. | Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction |
| DE19855963A1 (de) | 1998-12-04 | 2000-06-08 | Herbert Schott | Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung |
| MXPA01011517A (es) | 1999-05-12 | 2003-08-20 | Yamasa Corp | Nucleosidos de 4'-c-etinil-purina. |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| JP2004532184A (ja) | 2001-01-22 | 2004-10-21 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| WO2003070912A2 (en) | 2001-06-06 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2002097114A2 (en) | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
| EP1438054A4 (en) * | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| EP1435974A4 (en) | 2001-09-28 | 2006-09-06 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7125982B1 (en) | 2001-12-05 | 2006-10-24 | Frayne Consultants | Microbial production of nuclease resistant DNA, RNA, and oligo mixtures |
| EP1572705A2 (en) | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| US7323453B2 (en) | 2002-02-13 | 2008-01-29 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
| JP2005524662A (ja) | 2002-02-28 | 2005-08-18 | ビオタ インコーポレーティッド | ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ |
| WO2003100017A2 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| AU2003237249A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| AU2003269890A1 (en) | 2002-06-21 | 2004-01-06 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| EP1572945A2 (en) | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AP2005003211A0 (en) | 2002-06-28 | 2005-03-31 | Idenix Cayman Ltd | 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections. |
| CA2490191C (en) * | 2002-06-28 | 2010-08-03 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections |
| WO2004007512A2 (en) | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AU2003259735A1 (en) | 2002-08-08 | 2004-02-25 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
| WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US7393954B2 (en) | 2002-12-12 | 2008-07-01 | Reliable Biopharmaceutical Corporation | Process for the production of pentostatin aglycone and pentostatin |
| AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
| US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
| US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020884A2 (en) * | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| KR100883703B1 (ko) | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | 변형 불소화 뉴클레오시드 유사체 |
| US7507859B2 (en) | 2003-06-16 | 2009-03-24 | Fifth Base Llc | Functional synthetic molecules and macromolecules for gene delivery |
| KR20060084845A (ko) * | 2003-07-25 | 2006-07-25 | 이데닉스 (케이만) 리미티드 | Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체 |
| KR20060123707A (ko) | 2003-08-27 | 2006-12-04 | 바이오타, 인코포레이티드 | 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드 |
| RU2007102281A (ru) | 2004-06-23 | 2008-07-27 | Айденикс (Кайман) Лимитед (Ky) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae |
| EP1781101A2 (en) * | 2004-07-29 | 2007-05-09 | Metabasis Therapeutics, Inc. | Novel nucleoside derivatives |
| EP1828217A2 (en) | 2004-12-16 | 2007-09-05 | Febit Biotech GmbH | Polymerase-independent analysis of the sequence of polynucleotides |
| US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
| CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| US20100279974A1 (en) | 2005-03-09 | 2010-11-04 | Claire Pierra | Nucleosides With Non-Natural Bases as Anti-Viral Agents |
| EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| WO2006116512A1 (en) | 2005-04-26 | 2006-11-02 | The Board Of Trustees Of The University Of Illinois, Urbana, Il | Nucleoside compounds and methods of use thereof |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| BRPI0616738A2 (pt) | 2005-09-26 | 2011-06-28 | Pharmasset Inc | 4'-nucleosìdeos modificados como agentes antivirais |
| WO2007113538A1 (en) | 2006-04-03 | 2007-10-11 | Astrazeneca Ab | Substituted adenines and the uses thereof |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2114980B1 (en) | 2007-01-12 | 2012-06-27 | BioCryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| WO2008089439A2 (en) | 2007-01-18 | 2008-07-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| AU2008210411A1 (en) | 2007-01-31 | 2008-08-07 | Alios Biopharma, Inc. | 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents |
| JP2008214305A (ja) | 2007-03-07 | 2008-09-18 | Kotobuki Seiyaku Kk | 置換アミン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008115499A1 (en) | 2007-03-19 | 2008-09-25 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon | Mannich base n-oxide drugs |
| WO2008117047A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008127613A1 (en) | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
| PL2014771T3 (pl) | 2007-06-25 | 2015-05-29 | Anadys Pharmaceuticals Inc | Ciągły proces hydrolizy enzymatycznej |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| EP2220226A2 (en) | 2007-12-07 | 2010-08-25 | F. Hoffmann-La Roche AG | Hcv ns3 protease replicon shuttle vectors |
| WO2009086201A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents |
| WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
| PE20091492A1 (es) | 2008-02-22 | 2009-10-22 | Irm Llc | Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr |
| JP5628145B2 (ja) | 2008-03-19 | 2014-11-19 | ケムブリッジ・コーポレーション | 新規チロシンキナーゼ阻害剤 |
| CA2722308C (en) | 2008-04-15 | 2024-02-27 | Rfs Pharma, Llc. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US20110171192A1 (en) | 2008-09-05 | 2011-07-14 | Hiroshi Tomiyama | Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| US8163707B2 (en) | 2008-09-15 | 2012-04-24 | Enanta Pharmaceuticals, Inc. | 4′-allene-substituted nucleoside derivatives |
| US20100099079A1 (en) | 2008-09-26 | 2010-04-22 | Uprichard Susan L | Non-dividing cell-based assay for high throughput antiviral compound screening |
| US8716263B2 (en) * | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
| US20100240604A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| AP2011005929A0 (en) | 2009-03-20 | 2011-10-31 | Alios Biopharma Inc | Substituted nucleoside and nucleotide analogs. |
| HUE026647T2 (en) | 2009-05-08 | 2016-07-28 | Astellas Pharma Inc | Diamino heterocyclic carboxamide compound |
| EP2264169A1 (en) | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
| US20100331397A1 (en) | 2009-06-24 | 2010-12-30 | Alios Biopharma, Inc. | 2-5a analogs and their methods of use |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011057204A2 (en) | 2009-11-06 | 2011-05-12 | The Johns Hopkins University | Lrrk2-mediated neuronal toxicity |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| SG188497A1 (en) * | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
| AU2011305652B2 (en) | 2010-09-22 | 2016-10-20 | Janssen Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
| CN102516339B (zh) | 2010-10-21 | 2014-03-19 | 四川大学华西医院 | 嘧啶并嘧啶化合物及其核苷类似衍生物和制备方法及用途 |
| WO2012074547A2 (en) | 2010-11-29 | 2012-06-07 | New York University | STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF |
| EP2655392B1 (en) * | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| EP2697241B1 (en) | 2011-04-13 | 2019-06-12 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
| RU2640582C2 (ru) | 2011-08-01 | 2018-01-10 | Мбс Фарма, Инк. | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
| PL2794629T3 (pl) | 2011-12-20 | 2018-02-28 | Riboscience Llc | 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv |
| EP2794630A4 (en) * | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ME03502B (me) | 2012-03-21 | 2020-04-20 | Janssen Biopharma Inc | Supstituisani nukleozidi, nukleotidi i njihovi analozi |
| EP2828278A4 (en) | 2012-03-21 | 2015-12-09 | Alios Biopharma Inc | PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS |
| WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| CN102816197B (zh) | 2012-08-24 | 2015-04-29 | 四川大学华西医院 | 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用 |
| WO2014070771A1 (en) | 2012-10-29 | 2014-05-08 | Rfs Pharma, Llc | Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer |
| EP2935304A1 (en) * | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2935305A4 (en) | 2012-12-21 | 2016-08-03 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF |
| ES2865402T3 (es) * | 2012-12-21 | 2021-10-15 | Janssen Biopharma Inc | 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| NZ714927A (en) | 2013-05-16 | 2020-09-25 | Riboscience Llc | 4’-fluoro-2’-methyl substituted nucleoside derivatives |
| EP3013340B9 (en) | 2013-06-26 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| TWI655199B (zh) | 2013-06-26 | 2019-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| CA2952812A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
| NZ727582A (en) | 2014-06-24 | 2018-06-29 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015280248B2 (en) | 2014-06-24 | 2021-04-08 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP2017525681A (ja) | 2014-07-22 | 2017-09-07 | アリオス バイオファーマ インク． | パラミクソウイルスの治療方法 |
| SG11201700851WA (en) | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
| WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| WO2018031818A2 (en) | 2016-08-12 | 2018-02-15 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US20180117042A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2014
- 2014-10-09 JP JP2016521765A patent/JP6562908B2/ja active Active
- 2014-10-09 US US14/510,451 patent/US9862743B2/en active Active
- 2014-10-09 TW TW103135252A patent/TW201524990A/zh unknown
- 2014-10-09 SG SG10201804835VA patent/SG10201804835VA/en unknown
- 2014-10-09 MX MX2016004558A patent/MX382419B/es unknown
- 2014-10-09 EP EP14851776.6A patent/EP3055319A4/en not_active Withdrawn
- 2014-10-09 KR KR1020167011883A patent/KR102314960B1/ko not_active Expired - Fee Related
- 2014-10-09 AU AU2014331863A patent/AU2014331863C1/en not_active Ceased
- 2014-10-09 CA CA2927010A patent/CA2927010C/en active Active
- 2014-10-09 SG SG11201602595TA patent/SG11201602595TA/en unknown
- 2014-10-09 WO PCT/US2014/059849 patent/WO2015054465A1/en not_active Ceased
- 2014-10-09 PE PE2016000494A patent/PE20160658A1/es unknown
- 2014-10-09 CN CN201480064612.5A patent/CN105829333A/zh active Pending
- 2014-10-09 CN CN202110968375.7A patent/CN113712989A/zh active Pending
- 2014-10-09 EA EA201690526A patent/EA201690526A1/ru unknown
-
2016
- 2016-04-07 CL CL2016000805A patent/CL2016000805A1/es unknown
- 2016-04-08 MX MX2021001573A patent/MX2021001573A/es unknown
- 2016-04-10 IL IL245014A patent/IL245014B/en unknown
- 2016-04-11 PH PH12016500660A patent/PH12016500660A1/en unknown
-
2017
- 2017-10-23 US US15/790,764 patent/US10370401B2/en active Active
-
2019
- 2019-01-08 AU AU2019200096A patent/AU2019200096B2/en not_active Ceased
-
2020
- 2020-12-03 AU AU2020281091A patent/AU2020281091A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536288A5 (enExample) | ||
| JP2015510946A5 (enExample) | ||
| JP2012140432A5 (enExample) | ||
| JP2017513955A5 (enExample) | ||
| JP2014520767A5 (enExample) | ||
| JP2018528261A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| JP2015535847A5 (enExample) | ||
| JP2016523906A5 (enExample) | ||
| AR069494A1 (es) | Derivados de acidos fosfonicos | |
| EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
| JP2011219498A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| CY1114908T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| CA2556463A1 (en) | Dihydropyridinone derivatives | |
| HRP20211923T1 (hr) | Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za uporabu u liječenju neurodegenerativnih poremećaja | |
| AR089408A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos para ser empleados en el tratamiento de enfermedades virales | |
| JP2016523269A5 (enExample) | ||
| JP2010504908A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| CA2769553A1 (en) | Novel pyrimidine and triazine hepcidin antagonists | |
| EA200970655A1 (ru) | 6-замещенные пиримидины, ингибирующие вич |